Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 9/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23508113 | 0.82 | GSK3B (0.34) | ABL1SRCGSK3BCSNK2A1CDK2 | |
| SCHEMBL23497872 | 0.82 | CA12 (0.37) | ABL1SRCGSK3BPCSK9CSNK2A1 | |
| SCHEMBL23497703 | 0.77 | GSK3B (0.38) | ABL1SRCGSK3BPCSK9CSNK2A1 | |
| SCHEMBL23508105 | 0.76 | CDK2 (0.36) | GSK3BCDK2 | |
| SCHEMBL23497830 | 0.75 | HSD17B10 (0.46) | KDM4EALDH1A1 | |
| SCHEMBL23508128 | 0.75 | MEN1 (0.34) | GSK3BCDK2KDM4EALDH1A1CCNE1 | |
| SCHEMBL23508102 | 0.74 | — | — | |
| SCHEMBL23497487 | 0.74 | CDK2 (0.38) | ABL1SRCGSK3BCDK2CCNE1 | |
| SCHEMBL23508238 | 0.74 | PDE10A (0.43) | ABL1SRCGSK3BCDK2CCNE1 | |
| SCHEMBL30128675 | 0.73 | CDK2 (0.38) | ABL1GSK3BCDK2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BRCA1, TPX2, CCND2 | ABL1 2285/4885SRC 4260/4885GSK3B 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.